Healios K.K.
HLOSFOTCHealthcare● Active
$2.70
+$0.90(+50.00%)
Market Cap$290683229
P/E Ratio—
52W High$4.45
52W Low$1.8
Healios K.K. (HLOSF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HLOSF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.17
Est. -$0.07 · -148.2%
Revenue
$0.00B
Est. $0.00B · -70.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
HLOSF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$0.02 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.07 | -$0.17 | -148.2% | $0.00B | $0.00B | -70.9% |
| ▲ Q1 FY2026 | Feb 16, 2026 | $0.03 | $0.12 | +306.5% | $0.00B | $0.00B | -93.4% |
| ▼ Q3 FY2025 | Sep 30, 2025 | $0.04 | $0.03 | -23.4% | $0.00B | $0.01B | -97.7% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.05 | -$0.14 | -201.5% | $0.00B | $0.00B | -94.7% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.19 | -$0.18 | +5.1% | $0.00B | $0.00B | -89.4% |
| ▲ Q1 FY2025 | Feb 12, 2025 | -$0.07 | $0.02 | +124.4% | $0.00B | $0.00B | +620.0% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.08 | -$0.11 | -41.3% | $0.00B | $0.00B | +1214.5% |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.17
EPS Est.
-$0.07
EPS Surpr.
-148.2%
Revenue
$0.00B
Q1 FY2026
Feb 16, 2026Beat
EPS Actual
$0.12
EPS Est.
$0.03
EPS Surpr.
+306.5%
Revenue
$0.00B
Q3 FY2025
Sep 30, 2025Miss
EPS Actual
$0.03
EPS Est.
$0.04
EPS Surpr.
-23.4%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.05
EPS Surpr.
-201.5%
Revenue
$0.00B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.19
EPS Surpr.
+5.1%
Revenue
$0.00B
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.07
EPS Surpr.
+124.4%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.11
EPS Est.
-$0.08
EPS Surpr.
-41.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-9.76 | $-9.76 | $-9.76 | 1 |
| Q3 FY2027 | $-11.38 | $-11.38 | $-11.38 | 1 |
| Q2 FY2027 | $-12.42 | $-12.42 | $-12.42 | 1 |
| Q1 FY2027 | $-11.52 | $-11.52 | $-11.52 | 1 |
| Q4 FY2026 | $-8.45 | $-8.45 | $-8.45 | 1 |
| Q3 FY2026 | $-9.02 | $-9.02 | $-9.02 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.1B | $1.1B | $1.1B | 1 |
| Q3 FY2027 | $0.5B | $0.5B | $0.5B | 1 |
| Q2 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.4B | $0.4B | $0.4B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -148.2% | $2.20 | $2.20 | +0.00% |
| ▲ Q1 FY2026 | Feb 16, 2026 | +306.5% | $2.10 | $2.10 | +0.00% |
| ▼ Q3 FY2025 | Sep 30, 2025 | -23.4% | $4.15 | $4.15 | +0.00% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -201.5% | $4.45 | $4.45 | +0.00% |
| ▲ Q2 FY2025 | May 13, 2025 | +5.1% | $2.25 | $2.25 | +0.00% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +124.4% | $0.96 | $0.96 | +0.00% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -41.3% | $1.50 | $1.50 | +0.00% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -20.6% | $1.20 | $1.20 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 14, 2026
EPS Beat/Miss
-148.2%
Price Before
$2.20
Price After
$2.20
Q1 FY2026+0.00%
Report Date
Feb 16, 2026
EPS Beat/Miss
+306.5%
Price Before
$2.10
Price After
$2.10
Q3 FY2025+0.00%
Report Date
Sep 30, 2025
EPS Beat/Miss
-23.4%
Price Before
$4.15
Price After
$4.15
Q3 FY2025+0.00%
Report Date
Aug 12, 2025
EPS Beat/Miss
-201.5%
Price Before
$4.45
Price After
$4.45
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
+5.1%
Price Before
$2.25
Price After
$2.25
Q1 FY2025+0.00%
Report Date
Feb 12, 2025
EPS Beat/Miss
+124.4%
Price Before
$0.96
Price After
$0.96
Q4 FY2024+0.00%
Report Date
Nov 13, 2024
EPS Beat/Miss
-41.3%
Price Before
$1.50
Price After
$1.50
Q3 FY2024+0.00%
Report Date
Aug 13, 2024
EPS Beat/Miss
-20.6%
Price Before
$1.20
Price After
$1.20
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate3 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HLOSF ends December
Healios K.K. (HLOSF) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.17 — missing the analyst consensus of $-0.07 by -148.2%. The next HLOSF earnings date is expected around September 1, 2026.
Each quarter, investors track HLOSF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HLOSF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HLOSF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HLOSF earnings · 5 questionsHealios K.K.'s next earnings report is expected around September 1, 2026. HLOSF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HLOSF historically reports after market close (AMC).
HLOSF earnings datewhen is HLOSF earningsHLOSF next earnings datewhen does HLOSF report earningsHLOSF earnings calendar
▸ Source: FMP · Healios K.K. SEC filings · US GAAP · Healios K.K. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026